Actelion says lung drug macitentan submitted in Europe

ZURICH Actelion has submitted heart and lung drug macitentan to European health regulators, the second major step for the drug the Swiss group is positioning as a viable successor to its current top seller.

"The European Medicines Agency will now start the formal review process," Actelion said on Thursday. It plans to sell the drug under the brand name Opsumit.

Actelion, which submitted the treatment to the U.S. health regulator a month ago, issued data last month showing macitentan prolonged overall survival by more than a third in a clinical trial.

The company is banking on macitentan to replace top-seller Tracleer which, like macitentan, also treats pulmonary arterial hypertension (PAH) and currently accounts for around 90 percent of group sales. Tracleer goes off patent from 2015 and faces growing competition from Gilead's Letairis.

Actelion is continuing to prepare macitentan submissions in Switzerland and major markets around the world, the company said.

FRANKFURT AstraZeneca's immunotherapy drug durvalumab, the British drugmaker's most important pipeline medicine, has been accepted for review by U.S. regulators against bladder cancer, potentially its first use.

Reuters is the news and media division of Thomson Reuters. Thomson Reuters is the world's largest international multimedia news agency, providing investing news, world news, business news, technology news, headline news, small business news, news alerts, personal finance, stock market, and mutual funds information available on Reuters.com, video, mobile, and interactive television platforms. Learn more about Thomson Reuters products: